Christopher R. Cline, CHIEF FINANCIAL OFFICER at Travere Therapeutics, Inc. (TVTX), sold 2,491 shares at $46.65 ($115K) on 2026-05-05, disclosed to the SEC on 2026-05-06.
Scheduled sale ($115k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $46.65 | 2,181 | $102K | 88.2% |
| 2 | $43.95 | 310 | $14K | 11.8% |
| Total | $46.31 avg | 2,491 | $115K | 100% |
| Filing → |
| TVTX | SELL | 2026-04-15 | $349K | — | Filing → |
| TVTX | SELL | 2026-02-05 | $56K | — | Filing → |
| TVTX | SELL | 2026-02-03 | $233K | — | Filing → |